GSK receives FDA approval for a new self-injectable formulation of Benlysta (belimumab) for systemic lupus erythematosus

Saturday, July 22, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

GSK enquiries:

UK Media enquiries:

Simon Steel

+44 (0) 20 8047 5502

(London)

David Daley

+44 (0) 20 8047 5502

(London)

US Media enquiries:

Sarah Alspach

+1 202 715 1048

(Washington, DC)

Sarah Spencer

+1 215 751 3335

(Philadelphia)

Anna Padula

+1 215 751 4271

(Philadelphia)

Analyst/Investor enquiries:

Sarah Elton-Farr

+44 (0) 20 8047 5194

(London)

Tom Curry

+ 1 215 751 5419

(Philadelphia)

Gary Davies

+44 (0) 20 8047 5503

(London)

James Dodwell

+44 (0) 20 8047 2406

(London)

Jeff McLaughlin

+1 215 751 7002

(Philadelphia)



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store